The Menarini Group and its subsidiary Stemline Therapeutics: Menarini Group Shares New Analysis from EMERALD Clinical Study of ORSERDU (Elacestrant) in Metastatic Breast Cancer at ASCO 2023
ORSERDU (elacestrant) was approved by the FDA in January 2023 for estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with